No Data
Energy's Top 10 YTD Winners Riding Powerful Momentum Into the Second Half of 2026
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Royalty Pharma plc (NASDAQ:RPRX) on Wednesday entered into a $100 million funding agreement with Zealand Pharma in exchange for economic rights related to Zealand's product, Rusfertide (PTG-300).
Energy Earnings Beat: 10 Stocks With the Highest EPS Surprises
Keefe, Bruyette & Woods Maintains Market Perform on Enact Holdings, Raises Price Target to $49
Keefe, Bruyette & Woods analyst Bose George maintains Enact Holdings (NASDAQ:ACT) with a Market Perform and raises the price target from $44 to $49.
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings
Wholesale Used Car Prices Rise in July, Led by a Jolt in EV Pricing